Products with Anti-apoptotic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5944 | Liquiritin |
| Liquiritin possesses antidepressant-like, neuroprotective , antioxidant, antiapoptosis, anti-inflammatory and anti-cancer abilities. Liquiritin can attenuate advanced glycation end products-induced endothelial dysfunction via RAGE/NF-κB pathway in human umbilical vein endothelial cells, it may be a promising agent for the treatment of vasculopathy in diabetic patients. | |
| BCN5959 | Astragaloside |
| 1. Astragaloside may protect against brain contusion and neuronal apoptosis after TBI by attenuating microglia activation in male rats. 2. Astragaloside has several pharmacological actions on cardiovascular system, including positive inotropic, anti-arrhythmia and anti-oxidant activities; it also has anti-apoptotic activity, which may contribute to the improvement of clinical outcomes in treating myocarditis with pharmaceutics of Astragalus membranaceus. 3. Astragalosides-induced apoptosis in NB4 cells may be associated with down-regulation of the expression of BCL-2 and NF-κB, finally the relative activity of caspase-3 activated. | |
| BCN6105 | Vanillic acid |
| Vanillic acid is a flavoring agent which has hepatoprotective, free radical scavenging, antioxidant and anti-inflammatory properties. It exerts protective effects in isoproterenol induced cardiotoxic rats, has inhibitory effect on methylglyoxal-mediated glycation in apoptotic Neuro-2A cells via inhibition of glycation mechanisms including ROS, p38 and JNK, PKC and p47(phox). | |
| BCN6293 | Benzoylpaeoniflorin |
| Benzoylpaeoniflorin is active against cyclooxygenase(COX)-1 and COX-2 enzymes, it can restrain apoptosis of rats with coronary heart diseases by increasing the levels of Bc1-2 and decreasing the levels of Bax. | |
| BCN6295 | Cyclogalegigenin |
| 1. Cycloastragenol and astragaloside IV can suppress ROS-associated ER stress and then inhibit TXNIP/NLRP3 inflammasome activation with regulation of AMPK activity, and thereby ameliorate endothelial dysfunction by inhibiting inflammation and reducing cell apoptosis. 2. Cycloastragenol stimulates telomerase activity in human neonatal keratinocytes and rat neuronal cells, and induces CREB activation followed by tert and bcl2 expression, cycloastragenol may have a novel therapeutic role in depression. 3. Cycloastragenol can suppress the accumulation of cytoplasmic lipid droplet in 3T3-L1 adipocytes. 4. Cycloastragenol and astragaloside IV have been shown to improve the proliferative response of CD8+ T lymphocytes from HIV-infected patients by upregulating telomerase activity, they also may exert their cellular effects through the activation of the Src/MEK/ERK pathway. 5. Cycloastragenol can remarkably inhibit CYP3A4 and activate CYP2E1 in rats. 6. Cycloastragenol has been shown to extend T cell proliferation by increasing telomarase activity showing that it may also help delay the onset of cellular aging; it is an extraordinary wound healing agent; it inhibits the apoptosis of PC12 induced by 6-OHDA, may be as potential neuroprotective agents in the treatment of Parkinson's disease. | |
